Compare Recursion Pharmaceuticals Inc (RXRX) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sirius XM Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B), while Sirius XM Holdings Inc trades at $26.94 (market cap $8.87B). The key difference: Sirius XM Holdings Inc is far larger — about 4.1× Recursion Pharmaceuticals Inc's market cap, and Sirius XM Holdings Inc pays a 4.1% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Sirius XM Holdings Inc for 102 Days on average.
| RXRX | SIRI | |
|---|---|---|
Market Cap | $2.14B | $8.87B |
Volume | 30,789,535 | 4,324,672 |
Sector | Health | Media |
52-Week High | $6.79 | $32.59 |
52-Week Low | $2.84 | $19.92 |
Typical Hold Time | 22 Days | 102 Days |
Enterprise Value | $1.66B | $18.16B |
Dividend Yield | — | 4.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
SIRI trades at $25.95, down 1.56% with a bearish technical signal. The company shows mixed fundamentals with a P/E of 10.57 and P/B of 0.75 indicating potential undervaluation, but recent earnings misses and a significant net loss in 2024 raise concerns. Positive cash flow growth and a 62.5% analyst buy rating provide support, while the YouTube partnership offers growth potential.
The stock presents a value opportunity with upside to the $34.43 consensus target, but faces execution risks from subscription pressure and high debt. Recent institutional buying and management's focus on cash flow growth are positive catalysts, though technical weakness and competitive threats warrant caution for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
